This site is intended for healthcare professionals

Top-line results from phase III trials evaluating gefapixant (MK 7624) a treatment for refractory or unexplained chronic cough.- Merck Inc.

Read time: 1 mins
Published:25th Mar 2020
Condition: Chronic Cough
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest